Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ABT-450

Known as: ABT 450, ABT450 
 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Macrocyclic Compounds

Narrower (1)

paritaprevir

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.
BACKGROUND Interferon-containing regimens for the treatment of hepatitis C virus (HCV) infection are associated with increased… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2014
Highly Cited
2014
Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
BACKGROUND The interferon-free combination of the protease inhibitor ABT-450 with ritonavir (ABT-450/r) and the NS5A inhibitor… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2014
Highly Cited
2014
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.
BACKGROUND The interferon-free regimen of ABT-450 with ritonavir (ABT-450/r), ombitasvir, and dasabuvir with or without ribavirin… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
BACKGROUND In this phase 3 trial we evaluated the efficacy and safety of the interferon-free combination of ABT-450 with… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.
BACKGROUND & AIMS The interferon-free regimen of ABT-450 (a protease inhibitor), ritonavir, ombitasvir (an NS5A inhibitor… Expand
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
In Vitro and In Vivo Antiviral Activity and Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor ABT-450
ABSTRACT The development of direct-acting antiviral agents is a promising therapeutic advance in the treatment of hepatitis C… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
An interferon-free antiviral regimen for HCV after liver transplantation.
BACKGROUND Hepatitis C virus (HCV) infection is the leading indication for liver transplantation worldwide, and interferon… Expand
  • table 1
  • table 2
  • table 4
  • table 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
Therapy of hepatitis C--back to the future.
A book on hepatitis C would read like a marriage of an Orson Welles mystery and a Shakespearean play — awash in enigma, tragedy… Expand
  • table 1
  • table 1
Is this relevant?
Highly Cited
2014
Highly Cited
2014
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.
BACKGROUND An interferon-free combination of the protease inhibitor ABT-450 with ritonavir (ABT-450/r), the nonnucleoside… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2013
Highly Cited
2013
Exploratory study of oral combination antiviral therapy for hepatitis C.
BACKGROUND There is a need for interferon-free treatment regimens for hepatitis C virus (HCV) infection. The goal of this study… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE